Epidermal Growth Factor Receptor (EGFR) signaling promotes proliferation and survival in osteoprogenitors by increasing Early Growth Response Protein (Egr2) expression

Authors

Abhishek Chandra, Shenghui Lan, Ji Zhu, Valerie Siclari and Ling Qin

Abstract

Maintaining bone architecture requires continuous generation of osteoblasts from osteoprogenitor pool. Our previous study of mice with epidermal growth factor receptor (EGFR) specifically inactivated in osteoblast lineage cells revealed that EGFR stimulates bone formation by expanding the population of mesenchymal progenitors. EGFR ligands are potent regulators for the osteoprogenitor pool but the underlying mechanisms are largely unknown. Here we demonstrate that activation of EGFR increases the number of osteoprogenitors by promoting cell proliferation and suppressing either serum- or TNFα-induced apoptosis mainly through MAPK/Erk pathway. Mouse calvarial organ culture revealed that EGF elevated the number of proliferative cells and decreased the number of apoptotic cells, which lead to increased osteoblasts. Microarray analysis of MC3T3 cells, an osteoprogenitor cell line, revealed that EGFR signaling stimulates the expression of Mcl1, an anti-apoptotic protein, and a family of Egr transcription factors (Egr1, 2, and 3). The up-regulation of Mcl1 and Egr2 by EGF were further confirmed in osteoprogenitors close to the calvarial bone surface. Overexpression of Nab2, a co-repressor for Egrs, attenuated the EGF-induced increase in osteoprogenitor number. Interestingly, knocking down the expression of Egr2, but not Egr1 or 3, resulted in a similar effect. Using inhibitor, adenovirus overexpression, and siRNA approaches, we demonstrate that EGFR signaling activates MAPK/Erk pathway to stimulate the expression of Egr2, which in turn leads to cell growth and Mcl1-mediated cell survival. Taken together, our data clearly demonstrate that EGFR-induced Egr2 expression is critical for osteoprogenitor maintenance and new bone formation.

Link to Article

http://dx.doi.org/jbc.M112.447250

Growth Factor Directed Chondrogenic Differentiation of Porcine Bone Marrow–Derived Progenitor Cells

Authors

Harutsugi Abukawa, Brad S. Oriel, Jeremy Leaf, Joseph P. Vacanti, Leonard B. Kaban, Maria J. Troulis, Christopher J. Hartnick

Abstract

Background: Despite advances in surgical technique, reconstruction of a mandibular condyle still causes significant donor-site morbidity. The purpose of this study was to compare the effect of 3 different growth factors and define optimal cell culture conditions for bone marrow-derived progenitor cells to differentiate into chondrocytes for mandibular condyle reconstruction. Methods: Porcine bone marrow-derived progenitor cells (pBMPCs) were cultured as a pellet for 2, 3, and 4 weeks under the following conditions: group 1, TGF-β3 + standard medium; group 2, TGF-β3 + BMP-2 + standard medium; group 3, TGF-β3 + IGF-1 + standard medium; and group 4, TGF-β3 + BMP-2 + IGF-1 + standard medium. Chondrogenic differentiation was evaluated using 3 lineage differentiation markers. Results: The mean type II collagen positive area increased over weeks 2, 3, and 4 in group 4 compared to all the other groups (ANOVA; P = 0.005). At week 4, there was significantly greater type II collagen production in group 4 compared to all the other groups (ANOVA; P = 0.003). The medium in group 4 produces the greatest amount of cartilage when compared to groups 1, 2, and 3, and that 4 weeks produces the greatest amount of type II collagen. Conclusions: The results of this study indicate that the most efficacious medium for chondrogenic differentiation of pBMPCs was group 4 medium and the most type II collagen was produced at 4 weeks.

Link to Article

http://dx.doi.org/10.1097/SCS.0b013e31827ff323

Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model

Authors

Steven D. Rhodes, Xiaohua Wu, Yongzheng He, Shi Chen, Hao Yang, Karl W. Staser, Jiapeng Wang, Ping Zhang, Chang Jiang, Hiroki Yokota, Ruizhi Dong, Xianghong Peng, Xianlin Yang, Sreemala Murthy, Mohamad Azhar, Khalid S. Mohammad, Mingjiang Xu, Theresa A. Guise, Feng-Chun Yang

Abstract

Dysregulated TGF-β signaling is associated with a spectrum of osseous defects as seen in Loeys-Dietz syndrome, Marfan syndrome, and Camurati-Engelmann disease. Intriguingly, neurofibromatosis type 1 (NF1) patients exhibit many of these characteristic skeletal features including kyphoscoliosis, osteoporosis, tibial dysplasia, and pseudarthrosis; however, the molecular mechanisms mediating these phenotypes remain unclear. Here, we provide genetic and pharmacologic evidence that hyperactive TGF-β1 signaling pivotally underpins osseous defects in Nf1flox/-;Col2.3Cre mice, a model which closely recapitulates the skeletal abnormalities found in the human disease. Compared to controls, we show that serum TGF-β1 levels are 5–6 fold increased both in Nf1flox/-;Col2.3Cre mice and in a cohort of NF1 patients. Nf1 deficient osteoblasts, the principal source of TGF-β1 in bone, overexpress TGF-β1 in a gene dosage dependent fashion. Moreover, Nf1 deficient osteoblasts and osteoclasts are hyperresponsive to TGF-β1 stimulation, potentiating osteoclast bone resorptive activity while inhibiting osteoblast differentiation. These cellular phenotypes are further accompanied by p21-Ras dependent hyperactivation of the canonical TGF-β1-Smad pathway. Re-expression of the human, full-length neurofibromin GTPase-activating protein (GAP) related domain (NF1 GRD) in primary Nf1 deficient osteoblast progenitors, attenuated TGF-β1 expression levels and reduced Smad phosphorylation in response to TGF-β1 stimulation. As an in vivo proof of principle, we demonstrate that administration of the TβRI kinase inhibitor, SD-208, can rescue bone mass deficits and prevent tibial fracture non-union in Nf1flox/-;Col2.3Cre mice. In sum, these data demonstrate a pivotal role for hyperactive TGF-β1 signaling in the pathogenesis of NF1 associated osteoporosis and pseudarthrosis, thus implicating the TGF-β signaling pathway as a potential therapeutic target in the treatment of NF1 osseous defects which are refractory to current therapies.

Link to Article

http://dx.doi.org/10.1002/jbmr.1992

Gαo represses insulin secretion by reducing vesicular docking in pancreatic beta-cells

Authors

Aizhen Zhao, Mica Ohara-Imaizumi, Marcella Brissova, Richard K P Benninger, Yanwen Xu, Yuhan Hao, Joel Abramowitz, Guylain Boulay, Alvin C Powers, David Piston, Meisheng Jiang, Shinya Nagamatsu, Lutz Birnbaumer, Guoqiang Gu

Abstract

OBJECTIVE: Pertussis toxin uncoupling-based studies have shown that Gαi and Gαo can inhibit insulin secretion in pancreatic β-cells. Yet it is unclear whether Gαi and Gαo operate through identical mechanisms and how these G-protein-mediated signals inhibit insulin secretion in vivo. Our objective is to examine whether/how Gαo regulates islet development and insulin secretion in β-cells. RESEARCH DESIGN AND METHODS: Immunoassays were used to analyze the Gαo expression in mouse pancreatic cells. Gαo was specifically inactivated in pancreatic progenitor cells by pancreatic cell-specific gene deletion. Hormone expression and insulin secretion in response to different stimuli were assayed in vivo and in vitro. Electron microscope and total internal reflection fluorescence-based assays were used to evaluate how Gαo regulates insulin vesicle docking and secretion in response to glucose stimulation. RESULTS: Islet cells differentiate properly in Gαo(-/-) mutant mice. Gαo inactivation significantly enhances insulin secretion both in vivo and in isolation. Gαo nullizygous β-cells contain an increased number of insulin granules docked on the cell plasma membrane, although the total number of vesicles per β-cell remains unchanged. CONCLUSIONS: Gαo is not required for endocrine islet cell differentiation, but it regulates the number of insulin vesicles docked on the β-cell membrane.

Link to Article

http://dx.doi.org/10.2337/db09-1719

Bone Formation Under Sinus Using Venous Coagulum

Authors

Kathleen A Beaudry, DMD, MS, Nicolaas C Geurs, DDS, MS, Jack E Lemons, PhD, Michael S Reddy, DMD, DMSc

Abstract

Introduction: Insufficient bone height is a common obstacle to placing dental implants in the posterior maxilla. Sinus grafts have been shown to be a highly predictable way to increase bone height in the posterior maxilla. This case series illustrates a technique using venous coagulum and simultaneous implant placement under the elevated sinus. Bone formation is demonstrated clinically, radiographically, and histologically. To our knowledge, this is the first report of histomorphometric results and micro computed tomography using this technique. Case Presentation: A total of 5 sinus elevations with simultaneous placement of 2 dental implants were performed with venous blood coagulum as the sole filling biomaterial. At the time of uncovery, following 8-9 months healing, biopsies were harvested from the lateral wall of the maxilla. This article illustrates bone formation under 5 elevated sinuses, with simultaneous placement of dental implants, using venous coagulum as the sole filling material. Results show significant gains in bone height adjacent to the implant. MicroCT shows well-structured trabecular bone. Histomorphometry of biopsies show 38-74% vital bone. Conclusions: This case series illustrates that bone grafting materials in the subsinus cavity are not required for successful placement of implants. Utilization of ones own blood as filling material removes any objections to grafting including religious, ethical, or fear of disease transmission. Venous coagulum is a simple, inexpensive biomaterial and its systematic use during a sinus lift may be a relevant option, ultimately leading to increased access to implant treatment options for patients.

Link to Article

http://dx.doi.org/10.1902/cap.2013.120120

Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice

Authors

Karen A Dunphy, Anneke C Blackburn, Haoheng Yan, Lauren R O'Connell, D Joseph Jerry

Abstract

INTRODUCTION: Treatment with estrogen and progesterone (E+P) mimics the protective effect of parity on mammary tumors in rodents and depends upon the activity of p53. The following experiments tested whether exogenous E+P primes p53 to be more responsive to DNA damage and whether these pathways confer resistance to mammary tumors in a mouse model of Li-Fraumeni syndrome. METHODS: Mice that differ in p53 status (Trp53+/+, Trp53+/-, Trp53-/-) were treated with E+P for 14 days and then were tested for p53-dependent responses to ionizing radiation. Responses were also examined in parous and age-matched virgins. The effects of hormonal exposures on tumor incidence were examined in BALB/c-Trp53+/- mammary tissues. RESULTS: Nuclear accumulation of p53 and apoptotic responses were increased similarly in the mammary epithelium from E+P-treated and parous mice compared with placebo and age-matched virgins. This effect was sustained for at least 7 weeks after E+P treatment and did not depend on the continued presence of ovarian hormones. Hormone stimulation also enhanced apoptotic responses to ionizing radiation in BALB/c-Trp53+/- mice but these responses were intermediate compared with Trp53+/+ and Trp-/- tissues, indicating haploinsufficiency. The appearance of spontaneous mammary tumors was delayed by parity in BALB/c-Trp53+/- mice. The majority of tumors lacked estrogen receptor (ER), but ER+ tumors were observed in both nulliparous and parous mice. However, apoptotic responses to ionizing radiation and tumor incidence did not differ among outgrowths of epithelial transplants from E+P-treated donors and nulliparous donors. CONCLUSION: Therefore, E+P and parity confer a sustained increase in p53-mediated apoptosis within the mammary epithelium and suppress mammary tumorigenesis, but this effect was not retained in epithelial outgrowths.

Link to Article

http://dx.doi.org/10.1186/bcr2094